These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19818690)

  • 21. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.
    Passage E; Norreel JC; Noack-Fraissignes P; Sanguedolce V; Pizant J; Thirion X; Robaglia-Schlupp A; Pellissier JF; Fontés M
    Nat Med; 2004 Apr; 10(4):396-401. PubMed ID: 15034573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Motor axon loss is associated with hand dysfunction in Charcot-Marie-Tooth disease 1a.
    Videler AJ; van Dijk JP; Beelen A; de Visser M; Nollet F; van Schaik IN
    Neurology; 2008 Oct; 71(16):1254-60. PubMed ID: 18852440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomised, double blind, placebo controlled clinical trial.
    Petersen EE; Genet M; Caserini M; Palmieri R
    Arzneimittelforschung; 2011; 61(4):260-5. PubMed ID: 21650086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tripod pinch strength and thumb opposition are the major determinants of manual dexterity in Charcot-Marie-Tooth disease type 1A.
    Videler AJ; Beelen A; van Schaik IN; Verhamme C; van den Berg LH; de Visser M; Nollet F
    J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):828-33. PubMed ID: 20562406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients.
    Tozza S; Bruzzese D; Pisciotta C; Iodice R; Esposito M; Dubbioso R; Ruggiero L; Topa A; Spina E; Santoro L; Manganelli F
    Eur J Neurol; 2018 Feb; 25(2):301-306. PubMed ID: 29053907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo confocal microscopy of Meissner corpuscles as a novel sensory measure in CMT1A.
    Almodovar JL; Ferguson M; McDermott MP; Lewis RA; Shy ME; Herrmann DN
    J Peripher Nerv Syst; 2011 Sep; 16(3):169-74. PubMed ID: 22003930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric Charcot-Marie-Tooth disease type 1A.
    Burns J; Scheinberg A; Ryan MM; Rose KJ; Ouvrier RA
    Muscle Nerve; 2010 Aug; 42(2):262-7. PubMed ID: 20544937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of Charcot-Marie-Tooth Neuropathy Score in children with type 1A disease.
    Haberlová J; Seeman P
    Pediatr Neurol; 2010 Dec; 43(6):407-10. PubMed ID: 21093731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ascorbic acid for treatment in CMT1A: what's next?
    de Visser M; Verhamme C
    Lancet Neurol; 2011 Apr; 10(4):291-3. PubMed ID: 21393064
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of vitamin C vaginal tablets in the treatment of non-specific vaginitis. A randomised, double blind, placebo-controlled study.
    Petersen EE; Magnani P
    Eur J Obstet Gynecol Reprod Biol; 2004 Nov; 117(1):70-5. PubMed ID: 15474248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Animal models of Charcot-Marie-Tooth disease type 1A.
    Sereda MW; Nave KA
    Neuromolecular Med; 2006; 8(1-2):205-16. PubMed ID: 16775377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.
    van der Vaart T; Plasschaert E; Rietman AB; Renard M; Oostenbrink R; Vogels A; de Wit MC; Descheemaeker MJ; Vergouwe Y; Catsman-Berrevoets CE; Legius E; Elgersma Y; Moll HA
    Lancet Neurol; 2013 Nov; 12(11):1076-83. PubMed ID: 24090588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexistence of Charcot Marie Tooth disease type 1A and diabetes in Taiwan: A clinicopathological study.
    Chao HC; Chou CT; Lee YC; Lin KP
    J Neurol Sci; 2015 Nov; 358(1-2):213-20. PubMed ID: 26349404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ascorbic acid: a first generation drug for Charcot-Marie-Tooth disease].
    Fontès M
    Med Sci (Paris); 2004 Oct; 20(10):843-4. PubMed ID: 15461953
    [No Abstract]   [Full Text] [Related]  

  • 36. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Charcot-Marie-Tooth disease].
    Lee YC; Chang MH; Lin KP
    Acta Neurol Taiwan; 2008 Sep; 17(3):203-13. PubMed ID: 18975529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: a randomised, double-blind, sham-controlled trial.
    Burns J; Sman AD; Cornett KMD; Wojciechowski E; Walker T; Menezes MP; Mandarakas MR; Rose KJ; Bray P; Sampaio H; Farrar M; Refshauge KM; Raymond J;
    Lancet Child Adolesc Health; 2017 Oct; 1(2):106-113. PubMed ID: 30169201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.
    Meyer zu Horste G; Prukop T; Liebetanz D; Mobius W; Nave KA; Sereda MW
    Ann Neurol; 2007 Jan; 61(1):61-72. PubMed ID: 17262851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects.
    Mori L; Prada V; Signori A; Pareyson D; Piscosquito G; Padua L; Pazzaglia C; Fabrizi GM; Smania N; Picelli A; Schenone A;
    Eur J Phys Rehabil Med; 2019 Feb; 55(1):47-55. PubMed ID: 29898585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.